Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0029463 (osteosarcoma)
 16,637 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Researchers in the field of tumor suppressor genes are actively attempting to discover new tumor suppressor genes and/or characterize known tumor suppressor genes with the intention of treating and diagnosing cancers. A number of recent patents and patent applications have been published that discuss some of these discoveries. Some of the patents and patent applications discuss newly discovered tumor suppressor genes, including WW Domain-Containing Oxidoreductase (WWOX), Cancer Associated Ring-1 (CAR-1), Human Cervical Cancer Suppressor 1 (HCCS-1), Src-suppressed C kinase substrate (SSeCKS), ADP-Ribosylation factor-like putative Tumor Suppressor gene 1 (ARTS1), and Deleted in Osteosarcoma (DOS). One recent patent describes the discovery that known caspase family member caspase-8 (CASP8) is a tumor suppressor. Another recent patent describes the use of Wilms Tumor suppressor gene (WT1) peptides as a cancer vaccine. In addition, Sakai et al. received a patent describing a fragment of the p51 tumor suppressor gene containing a promoter region, which is useful for identifying compounds that modulate p51 activity. Another patent application recently published describes a chimeric tumor suppressor gene generated by combining a portion of the rat PEG-3 protein with the human GADD34 protein, thus creating a protein with apoptotic activity. These patents and patent applications provide valuable information that may be useful in fighting cancer by focusing on tumor suppressor gene activities.
 ...
PMID:Recent patents relating to tumor suppressor genes. 1907 17

Breakage of the fragile site FRA16D disrupts the WWOX (WW Domain Containing Oxidoreductase) tumor suppressor gene in osteosarcoma. However, the frequency of breakage is not sufficient to explain the rate of WWOX loss in pathogenesis. The involvement of non-coding RNA transcripts is proposed due to their accumulation at fragile sites, where they are advocated to influence specific chromosomal regions associated with malignancy. The long ncRNA PARTICLE (promoter of MAT2A antisense radiation-induced circulating long non-coding RNA) is transiently elevated in response to irradiation and influences epigenetic silencing modification within WWOX. It now emerges that elevated PARTICLE levels are significantly associated with FRA16D non-breakage in OS patients. Although not associated with overall survival, high PARTICLE levels were found to be significantly linked to metastasis free outcome. The transcription of both PARTICLE and WWOX are transiently responsive to exposure to low doses of radiation in osteosarcoma cell lines. Herein, a relationship between WWOX and PARTICLE transcription is suggested in human osteosarcoma cell lines representing alternative genetic backgrounds. PARTICLE over-expression ameliorated WWOX promoter activity in U2OS harboring FRA16D non-breakage. It can be concluded that the lncRNA PARTICLE influences the WWOX tumor suppressor and in the absence of WWOX FRA16D breakage, it is associated with OS metastasis-free survival.
 ...
PMID:The long non-coding RNA PARTICLE is associated with WWOX and the absence of FRA16D breakage in osteosarcoma patients. 2915 92